Smith & Nephew SNATS (SNN) Competitors

Smith & Nephew SNATS logo
$30.65 +0.14 (+0.45%)
As of 09:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.

SNN vs. GEHC, RMD, PHG, DXCM, and STE

Should you buy Smith & Nephew SNATS stock or one of its competitors? Smith & Nephew SNATS's main competitors and comparable companies include GE HealthCare Technologies (GEHC), ResMed (RMD), Koninklijke Philips (PHG), DexCom (DXCM), and STERIS (STE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Smith & Nephew SNATS compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

In the previous week, GE HealthCare Technologies had 8 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 13 mentions for GE HealthCare Technologies and 5 mentions for Smith & Nephew SNATS. GE HealthCare Technologies' average media sentiment score of 0.74 beat Smith & Nephew SNATS's score of 0.22 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GE HealthCare Technologies
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Smith & Nephew SNATS
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

GE HealthCare Technologies has a net margin of 9.96% compared to Smith & Nephew SNATS's net margin of 0.00%. GE HealthCare Technologies' return on equity of 20.45% beat Smith & Nephew SNATS's return on equity.

Company Net Margins Return on Equity Return on Assets
GE HealthCare Technologies9.96% 20.45% 5.97%
Smith & Nephew SNATS N/A N/A N/A

GE HealthCare Technologies currently has a consensus target price of $82.17, suggesting a potential upside of 0.41%. Smith & Nephew SNATS has a consensus target price of $31.91, suggesting a potential upside of 4.67%. Given Smith & Nephew SNATS's higher probable upside, analysts clearly believe Smith & Nephew SNATS is more favorable than GE HealthCare Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GE HealthCare Technologies
0 Sell rating(s)
11 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.52
Smith & Nephew SNATS
2 Sell rating(s)
8 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.91

GE HealthCare Technologies has higher revenue and earnings than Smith & Nephew SNATS.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GE HealthCare Technologies$20.63B1.79$2.08B$4.7417.27
Smith & Nephew SNATS$6.16B2.07$625MN/AN/A

GE HealthCare Technologies pays an annual dividend of $0.16 per share and has a dividend yield of 0.2%. Smith & Nephew SNATS pays an annual dividend of $0.59 per share and has a dividend yield of 1.9%. GE HealthCare Technologies pays out 3.4% of its earnings in the form of a dividend. GE HealthCare Technologies has increased its dividend for 1 consecutive years.

GE HealthCare Technologies has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

82.1% of GE HealthCare Technologies shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 0.4% of GE HealthCare Technologies shares are held by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

GE HealthCare Technologies beats Smith & Nephew SNATS on 12 of the 17 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to ResMed?

ResMed (NYSE:RMD) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

In the previous week, ResMed had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 9 mentions for ResMed and 5 mentions for Smith & Nephew SNATS. ResMed's average media sentiment score of 0.76 beat Smith & Nephew SNATS's score of 0.22 indicating that ResMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
7 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Smith & Nephew SNATS
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

ResMed has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

ResMed has a net margin of 27.79% compared to Smith & Nephew SNATS's net margin of 0.00%. ResMed's return on equity of 26.42% beat Smith & Nephew SNATS's return on equity.

Company Net Margins Return on Equity Return on Assets
ResMed27.79% 26.42% 19.43%
Smith & Nephew SNATS N/A N/A N/A

ResMed currently has a consensus price target of $253.69, suggesting a potential upside of 6.64%. Smith & Nephew SNATS has a consensus price target of $31.91, suggesting a potential upside of 4.67%. Given ResMed's stronger consensus rating and higher possible upside, equities analysts clearly believe ResMed is more favorable than Smith & Nephew SNATS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
0 Sell rating(s)
11 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.39
Smith & Nephew SNATS
2 Sell rating(s)
8 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.91

ResMed has higher earnings, but lower revenue than Smith & Nephew SNATS.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResMed$5.65B5.92$1.52B$10.9821.67
Smith & Nephew SNATS$6.16B2.07$625MN/AN/A

55.0% of ResMed shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 0.6% of ResMed shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.1%. Smith & Nephew SNATS pays an annual dividend of $0.59 per share and has a dividend yield of 1.9%. ResMed pays out 24.0% of its earnings in the form of a dividend. ResMed has raised its dividend for 13 consecutive years.

Summary

ResMed beats Smith & Nephew SNATS on 13 of the 17 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Koninklijke Philips has a net margin of 5.40% compared to Smith & Nephew SNATS's net margin of 0.00%. Koninklijke Philips' return on equity of 14.86% beat Smith & Nephew SNATS's return on equity.

Company Net Margins Return on Equity Return on Assets
Koninklijke Philips5.40% 14.86% 6.20%
Smith & Nephew SNATS N/A N/A N/A

Koninklijke Philips has higher revenue and earnings than Smith & Nephew SNATS.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Koninklijke Philips$20.17B1.46$1.01B$1.1725.53
Smith & Nephew SNATS$6.16B2.07$625MN/AN/A

Koninklijke Philips pays an annual dividend of $0.84 per share and has a dividend yield of 2.8%. Smith & Nephew SNATS pays an annual dividend of $0.59 per share and has a dividend yield of 1.9%. Koninklijke Philips pays out 71.8% of its earnings in the form of a dividend.

13.7% of Koninklijke Philips shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Koninklijke Philips has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

In the previous week, Smith & Nephew SNATS had 2 more articles in the media than Koninklijke Philips. MarketBeat recorded 5 mentions for Smith & Nephew SNATS and 3 mentions for Koninklijke Philips. Smith & Nephew SNATS's average media sentiment score of 0.22 beat Koninklijke Philips' score of -0.02 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Koninklijke Philips
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Smith & Nephew SNATS
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Smith & Nephew SNATS has a consensus price target of $31.91, suggesting a potential upside of 4.67%. Given Smith & Nephew SNATS's higher probable upside, analysts plainly believe Smith & Nephew SNATS is more favorable than Koninklijke Philips.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Koninklijke Philips
0 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Smith & Nephew SNATS
2 Sell rating(s)
8 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.91

Summary

Koninklijke Philips and Smith & Nephew SNATS tied by winning 8 of the 16 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to DexCom?

Smith & Nephew SNATS (NYSE:SNN) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

DexCom has a net margin of 19.42% compared to Smith & Nephew SNATS's net margin of 0.00%. DexCom's return on equity of 37.77% beat Smith & Nephew SNATS's return on equity.

Company Net Margins Return on Equity Return on Assets
Smith & Nephew SNATSN/A N/A N/A
DexCom 19.42%37.77%15.98%

Smith & Nephew SNATS currently has a consensus price target of $31.91, indicating a potential upside of 4.67%. DexCom has a consensus price target of $95.50, indicating a potential upside of 16.41%. Given DexCom's stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than Smith & Nephew SNATS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew SNATS
2 Sell rating(s)
8 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.91
DexCom
0 Sell rating(s)
2 Hold rating(s)
24 Buy rating(s)
2 Strong Buy rating(s)
3.00

DexCom has lower revenue, but higher earnings than Smith & Nephew SNATS.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew SNATS$6.16B2.07$625MN/AN/A
DexCom$4.66B6.56$836.30M$2.5532.17

In the previous week, DexCom had 5 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 10 mentions for DexCom and 5 mentions for Smith & Nephew SNATS. DexCom's average media sentiment score of 0.84 beat Smith & Nephew SNATS's score of 0.22 indicating that DexCom is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Smith & Nephew SNATS
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DexCom
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Smith & Nephew SNATS has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

Summary

DexCom beats Smith & Nephew SNATS on 13 of the 15 factors compared between the two stocks.

How does Smith & Nephew SNATS compare to STERIS?

Smith & Nephew SNATS (NYSE:SNN) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

STERIS has lower revenue, but higher earnings than Smith & Nephew SNATS.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew SNATS$6.16B2.07$625MN/AN/A
STERIS$5.94B4.21$782.30M$8.4330.54

STERIS has a net margin of 13.41% compared to Smith & Nephew SNATS's net margin of 0.00%. STERIS's return on equity of 14.80% beat Smith & Nephew SNATS's return on equity.

Company Net Margins Return on Equity Return on Assets
Smith & Nephew SNATSN/A N/A N/A
STERIS 13.41%14.80%9.99%

Smith & Nephew SNATS has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, STERIS has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Smith & Nephew SNATS pays an annual dividend of $0.59 per share and has a dividend yield of 1.9%. STERIS pays an annual dividend of $2.76 per share and has a dividend yield of 1.1%. STERIS pays out 32.7% of its earnings in the form of a dividend. STERIS has increased its dividend for 20 consecutive years.

Smith & Nephew SNATS currently has a consensus target price of $31.91, suggesting a potential upside of 4.67%. STERIS has a consensus target price of $283.50, suggesting a potential upside of 10.13%. Given STERIS's stronger consensus rating and higher probable upside, analysts clearly believe STERIS is more favorable than Smith & Nephew SNATS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew SNATS
2 Sell rating(s)
8 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.91
STERIS
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

In the previous week, STERIS had 8 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 13 mentions for STERIS and 5 mentions for Smith & Nephew SNATS. STERIS's average media sentiment score of 0.65 beat Smith & Nephew SNATS's score of 0.22 indicating that STERIS is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Smith & Nephew SNATS
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
STERIS
7 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

STERIS beats Smith & Nephew SNATS on 14 of the 17 factors compared between the two stocks.

Get Smith & Nephew SNATS News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNN vs. The Competition

MetricSmith & Nephew SNATSHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$12.80B$5.99B$7.83B$23.06B
Dividend Yield1.92%1.68%2.47%3.82%
P/E RatioN/A38.0633.9727.33
Price / Sales2.085.398.493.27
Price / Cash9.0323.6221.0115.54
Price / Book2.464.174.453.65
Net Income$625M$143.92M$3.52B$1.07B
7 Day Performance-1.35%-5.44%-5.94%-4.20%
1 Month Performance5.49%-3.64%-4.58%-2.47%
1 Year Performance-5.86%-0.05%-1.95%5.84%

Smith & Nephew SNATS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNN
Smith & Nephew SNATS
1.7711 of 5 stars
$30.65
+0.4%
$31.91
+4.1%
-6.4%$12.80B$6.16BN/A16,988
GEHC
GE HealthCare Technologies
3.8175 of 5 stars
$83.48
-0.7%
$80.87
-3.1%
+15.9%$37.74B$20.63B17.6154,000
RMD
ResMed
4.4138 of 5 stars
$232.77
-1.3%
$253.69
+9.0%
-2.9%$32.74B$5.65B21.2011,370
PHG
Koninklijke Philips
2.1768 of 5 stars
$30.39
-1.3%
N/A+6.6%$29.86B$20.17B26.0365,340
DXCM
DexCom
3.8298 of 5 stars
$80.04
-1.3%
$95.50
+19.3%
+40.3%$29.82B$4.66B31.3511,000

Related Companies and Tools


This page (NYSE:SNN) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners